What is Opdivo, and how does it work as a checkpoint inhibitor?
Opdivo (nivolumab) is an immune checkpoint inhibitor. It targets the PD-1 (programmed cell death 1) pathway to help the immune system recognize and attack cancer cells [1]. By blocking PD-1, it can increase T-cell activity in tumors [1].
What cancers is Opdivo used for?
Opdivo is used for multiple cancer types, including melanoma and lung cancer, among others [1]. The exact use depends on tumor type, stage, biomarkers, prior treatments, and whether it is given alone or combined with other therapies [1].
How is Opdivo given?
Opdivo is administered as an infusion (intravenous) in clinical care [1]. Dosing schedules depend on the cancer indication and the treatment regimen [1].
What side effects do patients ask about with checkpoint inhibitors like Opdivo?
Because Opdivo activates the immune system, it can cause immune-related adverse events. Commonly discussed categories include skin reactions, diarrhea/colitis, liver enzyme changes, lung inflammation, and endocrine effects such as thyroid problems, among others [1]. Any new or worsening symptoms during treatment should be reported promptly to the oncology team [1].
What happens if side effects occur—does treatment get stopped?
Immune-related side effects can require holding Opdivo and treating with supportive care or corticosteroids, depending on severity [1]. In some cases, treatment may be permanently discontinued for serious toxicity [1].
Opdivo vs other checkpoint inhibitors: how is it different from Keytruda and Tecentriq?
Opdivo is a PD-1 inhibitor, like pembrolizumab (Keytruda) and atezolizumab (Tecentriq, which targets PD-L1 rather than PD-1) [1]. Choice among these drugs depends on cancer type, trial evidence for that setting, biomarker status, combination partners, and patient factors [1].
Can Opdivo be combined with other therapies?
Yes. Checkpoint inhibitors are often used with other cancer treatments, including other immunotherapies or chemotherapy, depending on indication and clinical guidelines [1].
Who makes Opdivo, and what is its regulatory status?
Opdivo is an approved checkpoint inhibitor therapy in oncology [1]. Approval and indication-specific details come from regulatory labeling for each use case [1].
---
Sources
[1] https://www.opdivo.com/what-is-opdivo